Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP5522428B2 - Antibacterial and antifungal agents - Google Patents
[go: Go Back, main page]

JP5522428B2 - Antibacterial and antifungal agents - Google Patents

Antibacterial and antifungal agents Download PDF

Info

Publication number
JP5522428B2
JP5522428B2 JP2009075819A JP2009075819A JP5522428B2 JP 5522428 B2 JP5522428 B2 JP 5522428B2 JP 2009075819 A JP2009075819 A JP 2009075819A JP 2009075819 A JP2009075819 A JP 2009075819A JP 5522428 B2 JP5522428 B2 JP 5522428B2
Authority
JP
Japan
Prior art keywords
antibacterial
antifungal
test
silver
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009075819A
Other languages
Japanese (ja)
Other versions
JP2009256346A (en
Inventor
俊昭 米村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kochi University NUC
Original Assignee
Kochi University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kochi University NUC filed Critical Kochi University NUC
Priority to JP2009075819A priority Critical patent/JP5522428B2/en
Publication of JP2009256346A publication Critical patent/JP2009256346A/en
Application granted granted Critical
Publication of JP5522428B2 publication Critical patent/JP5522428B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Agricultural Chemicals And Associated Chemicals (AREA)

Description

本発明は、Co−Ag−Coの三核錯体を含有する抗菌・抗カビ剤に関するものである。本発明の抗菌・抗カビ剤は、例えば、紙、繊維、布帛、フィルターなどの紙・繊維製品類;木材、石膏ボードなどの建材製品のほか、フィルム、プラスチックなどの素材などに広く適用可能である。   The present invention relates to an antibacterial / antifungal agent containing a trinuclear complex of Co—Ag—Co. The antibacterial / antifungal agent of the present invention can be widely applied to, for example, paper and fiber products such as paper, fiber, fabric and filter; building material products such as wood and gypsum board, and materials such as film and plastic is there.

抗菌剤は、有機系抗菌剤と無機系抗菌剤に大別される。このうち無機系抗菌剤は、光や熱に弱く、ハロゲンなどにも鋭敏なため、耐久性に劣っている。また、長寿命の無機系抗菌剤として注目されている酸化チタンは、抗菌性発現のために光が必要であり、固体状態でしか加工できないなどの問題がある。このような耐久性や加工性などの問題は、無機系抗菌剤を紙、繊維、布帛などの基材に担持した抗菌製品の開発に大きな支障をもたらしている。また、抗菌製品には、好ましくは抗カビ性も更に有していることが要求され、抗菌性と抗カビ性の両特性を兼ね備えた抗菌・抗カビ剤の開発が望まれている。   Antibacterial agents are roughly classified into organic antibacterial agents and inorganic antibacterial agents. Among these, the inorganic antibacterial agents are inferior in durability because they are sensitive to light and heat and sensitive to halogens. In addition, titanium oxide, which is attracting attention as a long-life inorganic antibacterial agent, has a problem that it requires light for antibacterial properties and can only be processed in a solid state. Such problems such as durability and processability have seriously hindered the development of antibacterial products in which an inorganic antibacterial agent is supported on a substrate such as paper, fiber, or fabric. In addition, antibacterial products are preferably required to further have antifungal properties, and development of antibacterial and antifungal agents having both antibacterial and antifungal properties is desired.

銀イオンは、人体に対する毒性が低く、広い抗菌スペクトルを有しているため、種々の工業製品の抗菌処理に利用されている。例えば、特許文献1〜特許文献3には、銀錯体の抗菌剤が提案されている。本発明者らも、非特許文献1に、下式(5)のCo−Ag−Co三核錯体が大腸菌Y1090(E. coli strain Y1090)に対して優れた抗菌活性を有していることを報告している。この錯体は、モノチオラト−コバルト(III)錯体と銀(I)イオンとの反応によって得られ、AgとCoが硫黄(S)で架橋されたS架橋ヘテロ三核錯体である。 Silver ions are low in toxicity to the human body and have a broad antibacterial spectrum, and thus are used for antibacterial treatment of various industrial products. For example, Patent Documents 1 to 3 propose silver complex antibacterial agents. The present inventors also be in non-patent document 1 has excellent antibacterial activity against Co-Ag-Co trinuclear complex E. coli Y 1090 of the following formula (5) (E. coli strain Y1090 ) Has been reported. This complex is an S-bridged heterotrinuclear complex obtained by the reaction of a monothiolato-cobalt (III) complex and silver (I) ions, in which Ag and Co are bridged with sulfur (S).

特開2005−263712号公報JP 2005-263712 A 特開2000−86668号公報JP 2000-86668 A 特開2002−212444号公報JP 2002-212444 A

“Application of Co-Ag-Co trinuclear thiolato complexes toward eco-friendly type antimicrobial agent”、T.Yonemura、T.Ama、H.Kawaguchi、 Program No.635. 2005 Abstract Viewer、 The International Chemical Congress of Pacific Basin Societies“Application of Co-Ag-Co trinuclear thiolato complexes toward eco-friendly type antimicrobial agent”, T.Yonemura, T.Ama, H.Kawaguchi, Program No.635. 2005 Abstract Viewer, The International Chemical Congress of Pacific Basin Societies

本発明の目的は、抗菌性と抗カビ性の両特性に優れているほか、耐久性や加工性も良好な新規な抗菌・抗カビ剤を提供することにある。   An object of the present invention is to provide a novel antibacterial and antifungal agent which is excellent in both antibacterial and antifungal properties, and has excellent durability and processability.

上記課題を解決することのできた本発明の抗菌・抗カビ剤は、下式(1)で表されるCo−Ag−Coの三核錯体を含有するところに要旨を有している。   The antibacterial / antifungal agent of the present invention that has solved the above problems has a gist in that it contains a Co-Ag-Co trinuclear complex represented by the following formula (1).



式中、
nは1〜3の整数であり、
〜R12は同一または異なって、Hまたは炭素数が1〜6のアルキル基であり、
Nに結合するR〜Rのいずれかの基、R〜Rのいずれかの基、R〜R
いずれかの基、R10〜R12のいずれかの基は、他のいずれかの基と架橋結合を有
していても良く、
13は、Hまたは炭素数が1〜6のアルキル基である。


Where
n is an integer of 1 to 3,
R 1 to R 12 are the same or different and are H or an alkyl group having 1 to 6 carbon atoms;
Any group of R 1 to R 3 bonded to N, any group of R 4 to R 6 , any group of R 7 to R 9 , and any group of R 10 to R 12 It may have a crosslink with any group of
R 13 is H or an alkyl group having 1 to 6 carbon atoms.

本発明の好ましい抗菌・抗カビ剤は、下式(2)、下式(3)、および下式(4)で表されるCo−Ag−Coの三核錯体の少なくとも一種を含有している。   A preferred antibacterial / antifungal agent of the present invention contains at least one of a Co—Ag—Co trinuclear complex represented by the following formula (2), the following formula (3), and the following formula (4). .



式中、nおよびR13は前と同じ意味である。


In the formula, n and R 13 have the same meaning as before.

本発明の抗菌・抗カビ剤は、広範囲の抗菌性・抗カビ性を有し、耐光性、耐熱性、無機塩に対する安定性などの耐久性に優れているほか、溶液・固体のいずれの状態でも基材に適用可能であるなど加工性にも優れている。従って、本発明の抗菌・抗カビ剤は、様々な製品に適用可能であり、例えば、紙類、繊維・布帛、フィルター類のほか、木材などの建材製品、プラスチック類などの素材に利用することができる。   The antibacterial and antifungal agent of the present invention has a wide range of antibacterial and antifungal properties, and is excellent in durability such as light resistance, heat resistance, stability to inorganic salts, and in either a solution or solid state. However, it is excellent in workability, such as being applicable to a substrate. Accordingly, the antibacterial / antifungal agent of the present invention can be applied to various products, for example, paper, fibers / fabrics, filters, building materials such as wood, and materials such as plastics. Can do.

図1は、X線結晶構造解析の結果を示す図である。FIG. 1 is a diagram showing the results of X-ray crystal structure analysis. 図2は、核磁気共鳴(NMR)スペクトルの測定結果を示す図である。FIG. 2 is a diagram showing the measurement results of the nuclear magnetic resonance (NMR) spectrum. 図3は、可視−紫外(UV−Vis)吸収スペクトルの測定結果を示す図である。FIG. 3 is a diagram showing a measurement result of a visible-ultraviolet (UV-Vis) absorption spectrum. 図4は、赤外(IR)吸収スペクトルの測定結果を示す図である。FIG. 4 is a diagram showing measurement results of infrared (IR) absorption spectra. 図5は、実施例2において、固体状態および液体状態でのキセノン光照射下におけるUV−Vis吸収スペクトルの経時変化を示すグラフである。FIG. 5 is a graph showing the change with time of the UV-Vis absorption spectrum under irradiation with xenon light in the solid state and in the liquid state in Example 2. 図6は、実施例3において、無機塩を0.1%添加したときの波長650nmにおける吸光度の結果を示すグラフである。FIG. 6 is a graph showing the results of absorbance at a wavelength of 650 nm when 0.1% of an inorganic salt is added in Example 3.

本発明は、式(1)で表されるCo−Ag−Co三核錯体の新規用途発明に関するものである。式(1)には、非特許文献1に記載の式(5)の銀コバルト錯体も包含される。詳細には、後記する実施例に示すように、式(1)の銀コバルト錯体が、(ア)黄色ブドウ球菌、大腸菌、枯草菌、肺炎桿菌などに対する抗菌性に優れているだけでなく、クロコウジカビ、ススカビ、クロカビなどの抗カビ性にも優れており、広範囲の抗菌・抗カビ特性を有していること、(イ)光、熱、無機塩の共存下などにも安定で耐久性に優れていること、および(ウ)溶液・固体のいずれの状態でも紙類・布帛などの基材に適用可能であり加工性に優れていることを見出し、本発明を完成した。   The present invention relates to a novel use invention of the Co—Ag—Co trinuclear complex represented by the formula (1). Formula (1) also includes the silver cobalt complex of formula (5) described in Non-Patent Document 1. Specifically, as shown in the examples described later, the silver cobalt complex of the formula (1) is not only excellent in antibacterial activity against (a) Staphylococcus aureus, Escherichia coli, Bacillus subtilis, Klebsiella pneumoniae, etc. It has excellent anti-fungal properties such as Aspergillus, Susbi and Black mold, has a wide range of antibacterial and anti-fungal properties, and (i) stable and durable even in the presence of light, heat and inorganic salts. The present invention has been completed by finding that it is excellent and (c) it can be applied to substrates such as papers and fabrics in either a solution or solid state and is excellent in workability.

まず、本発明に用いられる式(1)の化合物について説明する。   First, the compound of formula (1) used in the present invention will be described.

上式(1)に示すように、本発明に用いられる化合物は、金属イオンとしてAg1個、Co2個を含み、配位子としてチオラト配位子、アミン配位子を有する銀コバルト錯体である。詳細には、Agイオンを中心核として持ち、AgとCoがSで架橋されたCo−Ag−Coの三核錯体であり、それぞれのSに(C1〜3)−C−NHが結合した構造を有している。前述した非特許文献1には、上式(1)に包含される式(2)の銀コバルト錯体(n=1、R13=H)について、特定の大腸菌(Y1090)に対する抗菌作用が報告されているだけで、当該化合物が、汎用の大腸菌(Escherichia coli)や、黄色ブドウ球菌などに対する抗菌性にも優れていることや、様々な種類のカビ類に対して優れた抗カビ作用を有することは報告されていない。後記する実施例で実証したように、上記化合物は、カビ類の最小発育阻止濃度(Minimum Inhibition Concentration、MIC)が非常に低く、銀イオンと同程度またはそれ以上の抗カビ作用を有していることが判明した。抗菌作用剤の多くは抗カビ作用を有していないことは周知であり、上式(1)の銀コバルト錯体が、広範囲の抗菌作用を発揮するだけでなく優れた抗カビ作用を有することは、本発明によって初めて見出された知見である。 As shown in the above formula (1), the compound used in the present invention is a silver cobalt complex containing 1 Ag and 2 Co as metal ions, and having a thiolato ligand and an amine ligand as ligands. Specifically, it is a trinuclear complex of Co—Ag—Co having Ag ions as a central nucleus and Ag and Co bridged by S, and (C 1-3 ) —C—NH 2 is bonded to each S. It has the structure. Non-Patent Document 1 described above reports antibacterial activity against a specific Escherichia coli (Y 1090 ) for the silver cobalt complex (n = 1, R 13 = H) of the formula (2) included in the above formula (1). This compound is excellent in antibacterial activity against general-purpose Escherichia coli and Staphylococcus aureus, and has excellent antifungal activity against various types of molds. Nothing has been reported. As demonstrated in the examples described later, the above compound has an extremely low minimum inhibitory concentration (MIC) of fungi, and has an antifungal activity equivalent to or higher than that of silver ions. It has been found. It is well known that many antibacterial agents do not have an antifungal action, and that the silver-cobalt complex of the above formula (1) not only exhibits a wide range of antibacterial actions but also has an excellent antifungal action. This is a finding first discovered by the present invention.

上記の錯イオンは+5価であり、アニオンとしては、例えば、NO、ClO、PF、BF、CFSOなどが挙げられ、下式で表される。
(NO)l(ClO)m(PF)n(BF)o(CFSO)p
式中、l、m、n、o、およびpは0〜5の整数であり、l+m+n+o+p=5である。
The complex ion is +5 valent, and examples of the anion include NO 3 , ClO 4 , PF 6 , BF 4 , and CF 3 SO 3, and are represented by the following formula.
(NO 3 ) l (ClO 4 ) m (PF 6 ) n (BF 4 ) o (CF 3 SO 3 ) p
In the formula, l, m, n, o, and p are integers of 0 to 5, and l + m + n + o + p = 5.

上式(1)において、Nに結合するR〜R12は、例えば、上式(2)〜上式(4)に示すように、架橋結合を有していることが好ましい。ただし、本発明はこれらに限定する趣旨ではない。本発明の抗菌・抗カビ剤は、式(2)〜式(4)の化合物を少なくとも一種含有することができる。 In the above formula (1), R 1 to R 12 bonded to N preferably have a crosslink as shown in the above formula (2) to the above formula (4), for example. However, the present invention is not limited to these. The antibacterial / antifungal agent of the present invention can contain at least one compound of formula (2) to formula (4).

本発明に用いられる銀コバルト錯体は、例えば、以下の方法で製造することができる。   The silver cobalt complex used for this invention can be manufactured with the following method, for example.

まず、コバルト錯体を製造する。具体的には、原料物質として、(ア)硝酸コバルトなどのCoイオン含有化合物と、(イ)2−アミノエタンチール、シスタミンなどの含硫黄アミン配位子;D,L−システイン、D,L−ペニシラミン等の含硫黄アミノ酸配位子などの含硫黄配位子と、(ウ)トリス(2−アミノエチル)アミン、トリエチレンテトラミン、エチレンジアミンなどの2〜4座のアミン配位子を水溶液中に徐々に加え、pHを約8.0〜8.5に調整しながら混合する。pHは、使用するアミン配位子の種類に応じて上記範囲内で適宜調整すれば良い。原料物質である上記(ア)〜(ウ)の比率は、使用するアミン配位子の種類によっても変化するが、おおむね、(ア):(イ):(ウ)=1:1:1〜1:1:2の比率(モル比)に制御することが好ましい。上記のpHを維持しながら、室温で90〜120分攪拌する。この反応液の不要物を濾過により取り除いた後、Coに対するモル比で2.5〜5倍当量程度の過塩素酸ナトリウム水溶液を加えると、コバルト錯体の結晶が得られる。   First, a cobalt complex is manufactured. Specifically, as raw materials, (a) a Co ion-containing compound such as cobalt nitrate, and (b) a sulfur-containing amine ligand such as 2-aminoethanethyl and cystamine; D, L-cysteine, D, L -Sulfur-containing ligands such as sulfur-containing amino acid ligands such as penicillamine and 2- or 4-dentate amine ligands such as (U) tris (2-aminoethyl) amine, triethylenetetramine, ethylenediamine in an aqueous solution. And then mixing while adjusting the pH to about 8.0-8.5. What is necessary is just to adjust pH suitably within the said range according to the kind of amine ligand to be used. The ratio of the above-mentioned raw materials (a) to (c) varies depending on the type of amine ligand used, but generally (a): (b): (c) = 1: 1: 1-1. It is preferable to control the ratio (molar ratio) to 1: 1: 2. While maintaining the above pH, the mixture is stirred at room temperature for 90 to 120 minutes. After removing unnecessary substances from the reaction solution by filtration, a cobalt complex crystal is obtained by adding an aqueous sodium perchlorate solution having a molar ratio to Co of about 2.5 to 5 times equivalent.

次に、このようにして得られたコバルト錯体にAgイオンを反応させる。具体的には、上記のコバルト錯体を蒸留水に溶かし、硝酸銀などのAgイオン含有化合物を、おおむね、Co:Ag=2:1の比率で加えて水溶液中(おおむね、30〜40℃)で反応させる。次いで、硝酸ナトリウムや過塩素酸ナトリウムなどを、Agに対するモル比で5倍当量程度、Coに対するモル比で2.5倍当量程度加えると、所望の銀コバルト錯体が得られる。後記する実施例では、含硫黄配位子として、2−アミノエタンチオールを用いた。   Next, Ag ions are reacted with the cobalt complex thus obtained. Specifically, the above cobalt complex is dissolved in distilled water, and an Ag ion-containing compound such as silver nitrate is generally added at a ratio of Co: Ag = 2: 1 and reacted in an aqueous solution (generally, 30 to 40 ° C.). Let Next, when sodium nitrate, sodium perchlorate, or the like is added in a molar ratio of about 5 times as much as Ag and a molar ratio of about 2.5 times as much as Co, a desired silver-cobalt complex is obtained. In Examples described later, 2-aminoethanethiol was used as the sulfur-containing ligand.

なお、後記する実施例では、上式(2)において、n=1、R13=Hである式(5)の化合物を製造して実験を行なったので、詳細は実施例を参照すれば良い。また、上式(3)や上式(4)の化合物は、チオラト配位子やアミン配位子の種類を変え、pHや反応温度などを適宜改変するなどして製造することができる。 In the examples described later, the experiment was carried out by producing the compound of the formula (5) in which n = 1 and R 13 = H in the above formula (2). Therefore, the examples may be referred to for details. . Further, the compounds of the above formula (3) and the above formula (4) can be produced by changing the kind of thiolate ligand or amine ligand and appropriately modifying pH, reaction temperature, and the like.

本発明の抗菌・抗カビ剤は、固体状態のままで使用しても良いし、水などの溶媒に溶解した溶液状態で使用しても良い。溶液状態で使用するときの濃度は、所望の抗菌・抗カビ作用が発揮されるように適宜調整すれば良いが、おおむね、0.1〜2.0質量%の濃度に調整して用いることが好ましい。   The antibacterial / antifungal agent of the present invention may be used in a solid state or in a solution state dissolved in a solvent such as water. The concentration when used in a solution state may be appropriately adjusted so that the desired antibacterial / antifungal action is exhibited, but it is generally adjusted to a concentration of 0.1 to 2.0% by mass. preferable.

また、本発明の抗菌・抗カビ剤は、基材と担持して使用することができる。   Further, the antibacterial / antifungal agent of the present invention can be used while being supported on a substrate.

本発明に用いられる基材は、抗菌・抗カビ剤を担持する抗菌・抗カビ製品に通常用いられるものであれば特に限定されず、例えば、紙、繊維、布帛、フィルターなどの紙・繊維製品類;木材、石膏ボードなどの建材製品;フィルム、プラスチック、金属、ガラスなどの素材などが挙げられる。後記する実施例で実証したように、本発明に用いられる銀コバルト錯体は、固体・液体のいずれの状態でも基材に適用可能であるため、加工性に極めて優れている。   The base material used in the present invention is not particularly limited as long as it is usually used for antibacterial / antifungal products carrying an antibacterial / antifungal agent. For example, paper / fiber products such as paper, fibers, fabrics, filters, etc. Kinds: Building materials such as wood and gypsum board; materials such as films, plastics, metals, and glass. As demonstrated in the examples described later, the silver-cobalt complex used in the present invention is extremely excellent in workability because it can be applied to the substrate in either a solid or liquid state.

本発明の抗菌・抗カビ剤を基材に担持し、成形物(製品)を得る方法は特に限定されず、基材の種類に応じて、通常用いられる方法を適宜採用すれば良い。例えば、基材を製品に加工した後、抗菌・抗カビ剤の溶液を当該製品の表面に被覆したり、当該製品に浸漬するなどの方法が挙げられる。あるいは、製品に加工する前に、基材と抗菌・抗カビ剤を混合するなどの方法を採用しても良い。   The method for obtaining the molded product (product) by supporting the antibacterial / antifungal agent of the present invention on a substrate is not particularly limited, and a generally used method may be appropriately employed depending on the type of the substrate. For example, after processing a base material into a product, a method of coating the surface of the product with an antibacterial / antifungal agent solution or immersing the product in the product may be used. Or you may employ | adopt methods, such as mixing a base material and an antibacterial and antifungal agent, before processing into a product.

基材に担持する抗菌・抗カビ剤の配合量は、使用する基材の種類や用途などに応じ、適宜適切に制御すればよい。例えば、紙類や布帛類などの基材に本発明の抗菌・抗カビ剤を用いる場合、基材全体に対し、おおむね、0.05〜0.5質量%を配合することが好ましい。   The blending amount of the antibacterial / antifungal agent supported on the base material may be appropriately controlled appropriately according to the type of the base material to be used and the application. For example, when the antibacterial / antifungal agent of the present invention is used for base materials such as papers and fabrics, it is preferable to add approximately 0.05 to 0.5% by mass with respect to the entire base material.

本発明の抗菌・抗カビ剤は、後記するように、優れた抗菌・抗カビ作用を有している。適用可能な細菌類としては、例えば、黄色ブドウ球菌Staphylococus aureus、大腸菌Escherichia coli、枯草菌Bacillus subtilis、肺炎桿菌Klebsiella pneumoniae subsp. Pneumoniaeなどの汎用菌が挙げられる。また、カビ類としては、風呂などの衛生加工品などに繁殖し易いクロコウジカビAspergillus niger、ススカビAlternaria alternate、クロカビCladosporium cladosporioidesなどが挙げられる。また、抗菌・抗カビ剤の配合量などを適切に制御すれば、食品などに繁殖し易いアオカビPenicillium citrinumなどにも適用可能である。また、酵母類などにも適用可能である。   As will be described later, the antibacterial / antifungal agent of the present invention has an excellent antibacterial / antifungal action. Examples of applicable bacteria include general-purpose bacteria such as Staphylococus aureus, Staphylococus aureus, Escherichia coli, Bacillus subtilis, Klebsiella pneumoniae subsp. Pneumoniae. Examples of molds include Aspergillus niger, Aspergillus niger, Alternaria alternate, and Black mold Cladosporium cladosporioides that are easy to breed in sanitary processed products such as baths. In addition, if the amount of antibacterial and antifungal agent is appropriately controlled, it can also be applied to blue mold Penicillium citrinum that is easy to reproduce in foods. It is also applicable to yeasts.

以下、実施例を挙げて本発明をより具体的に説明するが、本発明は下記実施例によって制限されず、前・後記の趣旨に適合し得る範囲で変更を加えて実施することも可能であり、それらは何れも本発明の技術的範囲に含まれる。   Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited by the following examples, and can be implemented with modifications within a range that can meet the purpose described above and below. They are all included in the technical scope of the present invention.

以下の実施例では、上式(5)の銀コバルト錯体を試料として用い、(ア)抗菌・抗カビ性(実施例1)、(イ)光および無機塩に対する耐久性(実施例2および3)、および(ウ)布帛に適用したときの抗菌・抗カビ性(実施例4)を調べた。   In the following examples, the silver cobalt complex of the above formula (5) was used as a sample, and (a) antibacterial and antifungal properties (Example 1), (b) durability against light and inorganic salts (Examples 2 and 3). ) And (c) Antibacterial and antifungal properties (Example 4) when applied to a fabric were examined.

本実施例に用いた銀コバルト錯体は、以下の方法で製造した。   The silver cobalt complex used for the present Example was manufactured with the following method.

まず、Co(NO・6HO28mmolを200cmの水に溶かし、これに2−アミノエタンチオール(「aet」と略記)28mmol水溶液50cmを加えた。さらにトリス(2−アミノエチル)アミン(「tren」と略記)28mmolの50cm水溶液をpH8.0に調整しながら徐々に加えた。pHを8.0に維持しながら室温で90分攪拌した。この反応液を自然濾過し、不要物を取り除いた。濾過後、140mmolのNaClO水溶液を加えて冷蔵庫に一晩放置すると、赤紫色の結晶が析出した。吸引濾過により濾液を濾別した後、メタノールと水(1:1)の混合溶媒50cmで洗浄し、アセトンで乾燥してコバルト錯体[Co(aet)(tren)](ClOを得た。 First, 28 mmol of Co (NO 3 ) 2 · 6H 2 O was dissolved in 200 cm 3 of water, and 50 cm 3 of a 28 mmol aqueous solution of 2-aminoethanethiol (abbreviated as “aet”) was added thereto. Furthermore, a 50 cm 3 aqueous solution of 28 mmol of tris (2-aminoethyl) amine (abbreviated as “tren”) was gradually added while adjusting the pH to 8.0. The mixture was stirred at room temperature for 90 minutes while maintaining the pH at 8.0. The reaction solution was naturally filtered to remove unnecessary substances. After filtration, 140 mmol of NaClO 4 aqueous solution was added and left in the refrigerator overnight to deposit reddish purple crystals. The filtrate was separated by suction filtration, washed with 50 cm 3 of a mixed solvent of methanol and water (1: 1), and dried with acetone to obtain a cobalt complex [Co (aet) (tren)] (ClO 4 ) 2 . It was.

次に、生成した[Co(aet)(tren)](ClO2.4mmolを60cmの蒸留水に溶かし、これに少量の蒸留水に溶かしたAgNO1.2mmolを加え、30℃で5時間攪拌した。反応液を濾過した後、少量の蒸留水に溶かしたNaClOを6mmol加えると赤色の結晶または粉末が析出した。これを吸引濾過して結晶または粉末を濾取した後、冷水で洗浄し、所望とする銀コバルト錯体である式(5)の化合物を得た。 Next, 2.4 mmol of the produced [Co (aet) (tren)] (ClO 4 ) 2 was dissolved in 60 cm 3 of distilled water, and 1.2 mmol of AgNO 3 dissolved in a small amount of distilled water was added thereto, and 30 ° C. For 5 hours. After filtering the reaction solution, 6 mmol of NaClO 4 dissolved in a small amount of distilled water was added to precipitate red crystals or powder. This was subjected to suction filtration to collect crystals or powder, and then washed with cold water to obtain a compound of formula (5) which is a desired silver cobalt complex.

このようにして得られた化合物の立体構造を明らかにするため、X線結晶構造解析、および核磁気共鳴(NMR)スペクトルの測定を行なった。図1にX線結晶構造解析の結果を、図2にNMRスペクトルの結果を、それぞれ示す。また、可視−紫外(UV−Vis)、赤外(IR)吸収スペクトルの測定を行い、分光学的特性を調べた。その結果を図3、4に示す。   In order to clarify the three-dimensional structure of the compound thus obtained, X-ray crystal structure analysis and nuclear magnetic resonance (NMR) spectrum measurement were performed. FIG. 1 shows the result of X-ray crystal structure analysis, and FIG. 2 shows the result of NMR spectrum. Further, visible-ultraviolet (UV-Vis) and infrared (IR) absorption spectra were measured, and spectroscopic characteristics were examined. The results are shown in FIGS.

実施例1 銀コバルト錯体の抗菌・抗カビ試験
本実施例では、上記の方法で得られた銀コバルト錯体を用い、以下のようにして抗菌・抗カビ試験を行なった。
(1)試験に用いた試料溶液の調製
上記の銀コバルト錯体を水に溶解して1000ppm濃度の試料溶液を得た。この溶液を2倍系列で希釈し、500ppm、250ppm、125ppm、63ppm、32ppm、16ppm、8ppm、4ppm、2ppmの各濃度に調製した。比較のため、銀イオン(硝酸銀AgNO)を用い、上記と同様の各濃度に調製した。
(2)抗菌試験
(2−1)試験菌液の調製
試験細菌として、黄色ブドウ球菌Staphylococus aureus、大腸菌Escherichia coli、枯草菌Bacillus subtilis、肺炎桿菌Klebsiella pneumoniae subsp. Pneumoniaeを用いた。
Example 1 Antibacterial / Antifungal Test of Silver Cobalt Complex In this example, an antibacterial / antifungal test was performed as follows using the silver cobalt complex obtained by the above method.
(1) Preparation of sample solution used in test The above-described silver cobalt complex was dissolved in water to obtain a sample solution having a concentration of 1000 ppm. This solution was diluted in a series of 2 to prepare 500 ppm, 250 ppm, 125 ppm, 63 ppm, 32 ppm, 16 ppm, 8 ppm, 4 ppm, and 2 ppm concentrations. For comparison, silver ions (silver nitrate AgNO 3 ) were used to prepare the same concentrations as described above.
(2) Antibacterial test
(2-1) Preparation of test bacterial solution As test bacteria, Staphylococus aureus, Escherichia coli, Bacillus subtilis, Bacillus subtilis Klebsiella pneumoniae subsp. Pneumoniae was used.

上記の各細菌を普通寒天培地(NA、ニッスイ)に接種し、35℃で24時間培養した後、生理食塩水を用いて細菌の菌数が108個/mLになるように調製したものを試験菌液とした。 After inoculating each of the above bacteria on a normal agar medium (NA, Nissui), culturing at 35 ° C. for 24 hours, and using physiological saline to prepare a bacterial count of 10 8 / mL A test bacterial solution was used.

(2−2)試験方法
上記のようにして得た各濃度の試料溶液に試験菌液を0.1mL接種し、35℃で24時間培養した。培養後、細菌の発育の有無を肉眼で観察し、MIC(ppm)を判定した。
(2-2) Test Method 0.1 mL of the test bacterial solution was inoculated into the sample solution of each concentration obtained as described above, and cultured at 35 ° C. for 24 hours. After culturing, the presence or absence of bacterial growth was observed with the naked eye, and MIC (ppm) was determined.

(3)抗カビ試験
(3−1)試験胞子液の調製
試験カビとして、クロコウジカビAspergillus niger、ススカビAlternaria alternate
、クロカビCladosporium cladosporioidesを用いた。
(3) Antifungal test
(3-1) Preparation of test spore solution As test mold, Aspergillus niger, Susukabi Alternaria alternate
The black mold, Cladosporium cladosporioides, was used.

上記の各カビをポテトデキストロース寒天培地に接種し、25℃で7日間培養した後、0.05%tween80液(界面活性剤Poly(Oxyethylene)sorbitan monooleate)を用いて胞子の個数が10/mLになるように調製したものを試験胞子液とした。 Each mold is inoculated on a potato dextrose agar medium, cultured at 25 ° C. for 7 days, and then the number of spores is 10 8 / mL using 0.05% tween 80 solution (surfactant Poly (Oxyethylene) sorbitan monooleate). The test spore solution was prepared as follows.

(3−2)試験方法
上記のようにして得た各濃度の試料溶液に試験胞子液を0.1mL接種し、25℃で7日間培養した。培養後、カビの発育の有無を肉眼で観察し、MIC(ppm)を判定した。
(3-2) Test Method Each sample solution obtained as described above was inoculated with 0.1 mL of the test spore solution and cultured at 25 ° C. for 7 days. After culturing, the presence or absence of mold growth was observed with the naked eye, and MIC (ppm) was determined.

これらの結果を表1〜表7に示す。MICが小さい程、抗菌性/抗カビ性に優れていることを意味する。   These results are shown in Tables 1-7. The smaller the MIC, the better the antibacterial / antifungal properties.

これらの表より、以下のように考察することができる。   From these tables, it can be considered as follows.

まず、抗菌性について検討すると、本発明例は、銀イオンに比べ、黄色ブドウ球菌に対する抗菌性に特に優れていることが分かる。また、他の細菌に対する抗菌作用も、概ね、良好であることが確認された。   First, when antibacterial properties are examined, it can be seen that the inventive examples are particularly superior in antibacterial properties against Staphylococcus aureus as compared with silver ions. It was also confirmed that the antibacterial action against other bacteria was generally good.

次に、抗カビ性について検討すると、本発明例は、銀イオンに比べ、クロカビに対する抗カビ性に特に優れており、他のカビ類についても銀イオンと同程度の作用が確認された。   Next, the antifungal property was examined. The present invention example was particularly superior in antifungal property against black mold as compared with silver ion, and other fungi were confirmed to have the same effect as silver ion.

このように本発明例は、特に広い抗カビスペクトルを有している点で、銀イオンよりも抗菌・抗カビ剤として有用であることが分かった。   Thus, it turned out that the example of this invention is more useful as an antibacterial and antifungal agent than silver ion in that it has a particularly wide antifungal spectrum.

実施例2 耐光性試験
本実施例では、上記の方法で得られた銀コバルト錯体を用い、固体状態および液体状態での光(紫外光)に対する安定性を調べた。固体試料および液体試料は、いずれも、上記の銀コバルト錯体の粉末を用いて調製した。
Example 2 Light Resistance Test In this example, the stability to light (ultraviolet light) in a solid state and a liquid state was examined using the silver cobalt complex obtained by the above method. Both the solid sample and the liquid sample were prepared using the powder of the silver cobalt complex.

(1)固体試料での耐光性試験
まず、試料(粉末)を5.25×10-5mol量り取り、200Wキセノン光を照射
したときのUV−Vis吸収スペクトルの時間変化を測定した。ここでは、浜松フォトニクス社製「L3451−01型」の紫外線照射装置(200W水銀−キセノンランプ)を使用した。ライト・ガイドの光出射口からの距離は15cmに固定した。照射後0、2時間、40時間に7.5×10-6molを量り取り、5mlメスフラスコを用いて1.5mmol・dm−3の水溶液を調製し、UV−Vis吸収スペクトル(650〜350nm領域)を測定した。
(1) Light resistance test on solid sample First, 5.25 × 10 −5 mol of a sample (powder) was weighed, and the time change of the UV-Vis absorption spectrum when irradiated with 200 W xenon light was measured. Here, an “L3451-01 type” ultraviolet irradiation device (200 W mercury-xenon lamp) manufactured by Hamamatsu Photonics was used. The distance from the light exit of the light guide was fixed at 15 cm. 7.5 × 10 −6 mol was weighed at 0, 2 and 40 hours after irradiation to prepare a 1.5 mmol · dm −3 aqueous solution using a 5 ml volumetric flask, and UV-Vis absorption spectrum (650 to 350 nm). Area).

(2)溶液試料での耐光性試験
試料(粉末)を7.5×10-5mol量り取り、50mlメスフラスコを用いて1.5mmol・dm−3溶液を調製した。これをビーカーに移し、上記(1)と同様にして紫外光照射を行い、0、30分、60分、90分、120分後に、UV−Vis吸収スペクトル(650〜350nm領域)を測定した。
(2) Light resistance test with solution sample A sample (powder) was weighed in 7.5 × 10 −5 mol, and a 1.5 mmol · dm −3 solution was prepared using a 50 ml volumetric flask. This was transferred to a beaker, irradiated with ultraviolet light in the same manner as in (1) above, and UV-Vis absorption spectrum (650 to 350 nm region) was measured after 0, 30, 60, 90 and 120 minutes.

これらの結果を図5に示す。図5に示すように、固体状態では、40時間という長時間の光照射下でも、スペクトルの変化は殆ど認められなかった。また、水溶液状態では、照射時間を長くするとスペクトルの変化が若干観察されたが、大きな変化は見られなかった。従って、本発明例は、固体状態でも液体状態でも、光に対する安定性に優れていることが確認された。   These results are shown in FIG. As shown in FIG. 5, in the solid state, almost no change in the spectrum was observed even under light irradiation for a long time of 40 hours. In the aqueous solution state, a slight change in the spectrum was observed when the irradiation time was lengthened, but no significant change was observed. Therefore, it was confirmed that the examples of the present invention are excellent in light stability both in the solid state and in the liquid state.

実施例3 無機塩の影響
本実施例では、共存塩イオンの影響を調べるため、上記の方法で得られた銀コバルト錯体に種々のアルカリ金属塩およびアルカリ土類金属塩を添加したときの、大腸菌に対する抗菌性の影響を調べた。
Example 3 Influence of inorganic salt In this example, in order to investigate the influence of coexisting salt ions, E. coli when various alkali metal salts and alkaline earth metal salts were added to the silver-cobalt complex obtained by the above method. The antibacterial effect on was investigated.

まず、上記のようにして得られた試料の溶液を0.5mL(濃度は2000ppm)を用意した。また、大腸菌Y1090(E. Coli strain Y1090)をLB(Luria−Bertani)液体培地(bacto tryptone:10g、bacto yeast extract:5g、NaCl:10g、5NのNaOH:0.2mlを水1Lに溶解して調製)に接種し、35℃で24時間培養した後、LB液体培地を用いて20倍に希釈したものを試験菌液とした。 First, 0.5 mL (the concentration was 2000 ppm) of the sample solution obtained as described above was prepared. Also, E. coli Y 1090 (E. Coli strain Y1090) is dissolved in 1 L of water in LB (Luria-Bertani) liquid medium (bacto tryptone: 10 g, bacto yeast extract: 5 g, NaCl: 10 g, 5N NaOH: 0.2 ml). Prepared), cultured at 35 ° C. for 24 hours, and diluted 20-fold with LB liquid medium to obtain a test bacterial solution.

上記の試料溶液0.5mLを試験菌液4.5mLに添加し、試料濃度が200ppmの溶液を調製した。この溶液に、図6に示す種々のアルカリ金属塩およびアルカリ土類金属塩の濃度が1000ppm(0.1%)になるように添加した溶液を調製し、抗菌活性に及ぼす各種無機塩類の影響を以下のようにして評価した。   0.5 mL of the above sample solution was added to 4.5 mL of the test bacterial solution to prepare a solution having a sample concentration of 200 ppm. A solution was prepared by adding various alkali metal salts and alkaline earth metal salts shown in FIG. 6 to a concentration of 1000 ppm (0.1%), and the effects of various inorganic salts on antibacterial activity were prepared. Evaluation was performed as follows.

具体的には、上記のようにして得られた溶液を試験管にいれ、37℃で18時間振とう培養を行い、可視−紫外(UV−Vis)分光光度計を用いて波長650nmにおける吸光度(濁度)を測定した。比較のため、無機塩および試料を添加しないものを用意し、上記と同様にして吸光度を測定した。   Specifically, the solution obtained as described above is placed in a test tube, cultured with shaking at 37 ° C. for 18 hours, and the absorbance at a wavelength of 650 nm using a visible-ultraviolet (UV-Vis) spectrophotometer ( Turbidity) was measured. For comparison, an inorganic salt and a sample to which no sample was added were prepared, and the absorbance was measured in the same manner as described above.

無機塩の濃度が0.1%の結果を図6に示す。   The result when the concentration of the inorganic salt is 0.1% is shown in FIG.

この図より、アルカリ金属およびアルカリ土類金属の塩化物、硝酸塩、硫酸塩、炭酸塩を0.1%添加しても、抗菌活性には影響を及ぼさないことが分かった。さらに、塩化物を用いた場合でも塩化銀の白濁は見られず、ハロゲン化物イオンに対する耐性があることも分かった。   From this figure, it was found that the addition of 0.1% of alkali metal and alkaline earth metal chlorides, nitrates, sulfates and carbonates did not affect the antibacterial activity. Furthermore, even when chloride was used, silver turbidity of silver chloride was not observed, and it was also found that it was resistant to halide ions.

実施例4 銀コバルト錯体を布帛に塗布した後の光照射後における抗菌・抗カビ試験
本実施例では、上記のようにして得られた銀コバルト錯体を布帛(基材)に塗布し、耐光性試験を行なった後の抗菌・抗カビ性を調べた。
Example 4 Antibacterial / Antifungal Test after Light Irradiation after Applying Silver Cobalt Complex to Fabric In this example, the silver cobalt complex obtained as described above was applied to a fabric (base material), and light resistance was obtained. Antibacterial and antifungal properties were examined after the test.

(1)試験菌液の調製
本実施例では、試験細菌として、黄色ブドウ球菌Staphylococus aureus、大腸菌Escherichia coli、枯草菌Bacillus subtilis、肺炎桿菌Klebsiella pneumoniae subsp. Pneumoniaeを用いた。
(1) Preparation of test bacterial solution In this example, Staphylococus aureus, Escherichia coli, Bacillus subtilis, and Klebsiella pneumoniae subsp. Pneumoniae were used as test bacteria.

上記の試験細菌を普通寒天培地(NA、ニッスイ)に接種し、35℃で24時間培養した。これを20倍に希釈した普通ブイヨンを用い、菌数が10/mLのオーダーになるように調製したものを試験菌液とした。 The above test bacteria were inoculated on a normal agar medium (NA, Nissui) and cultured at 35 ° C. for 24 hours. An ordinary bouillon diluted 20 times was used to prepare a test bacterial solution prepared so that the number of bacteria was on the order of 10 5 / mL.

(2)試験胞子液の調製
本実施例では、試験カビとして、ススカビAlternaria alternate、クロカビCladosporium cladosporioidesを用いた。
(2) Preparation of test spore solution In this example, as a test mold, Susukabi Alternaria alternate and Black mold Cladosporium cladosporioides were used.

上記の各カビをポテトデキストロース寒天培地に接種し、25℃で7日間培養した後、20倍に希釈したブドウ糖ペプトン培地(Glucose Peptone Broth)を用いて胞子の個数が10/mLのオーダーになるように調製したものを試験胞子液とした。 Each mold is inoculated on a potato dextrose agar medium, cultured for 7 days at 25 ° C., and then the number of spores is on the order of 10 5 / mL using a 20-fold diluted glucose peptone medium (Glucose Peptone Broth). What was prepared in this way was used as a test spore solution.

(3)基材
本実施例では、スパンレース不織布(三昭紙業株式会社製のKP9380)を用いた。
(3) Substrate In this example, a spunlace nonwoven fabric (KP9380 manufactured by Sansho Paper Industry Co., Ltd.) was used.

(4)試験検体の調製
まず、上記のようにして得られた銀コバルト錯体に水を添加し、濃度が4000ppmになるように調製した。次いで、この溶液を基材に塗布し、銀コバルト錯体含浸基材を得た。塗布には霧吹き器を用いた。また、基材への塗布濃度は、塗布前後の重量変化から当該濃度が3000ppmになるように調製した。
(4) Preparation of test specimen First, water was added to the silver-cobalt complex obtained as described above to prepare a concentration of 4000 ppm. Subsequently, this solution was apply | coated to the base material and the silver cobalt complex impregnation base material was obtained. A sprayer was used for application. The coating concentration on the substrate was adjusted so that the concentration was 3000 ppm from the weight change before and after coating.

このようにして得られた銀コバルト錯体含浸基材に対し、28℃で照射照度550W/mで100時間照射(これは、直射日光下で約1年間照射に相当する。)を行った。照射後の基材を無菌的に細かく切り、滅菌アンプル瓶に0.4g入れたものを試験検体とした。 The silver-cobalt complex-impregnated substrate thus obtained was irradiated for 100 hours at 28 ° C. and an irradiation illuminance of 550 W / m 2 (this corresponds to irradiation for about one year under direct sunlight). The substrate after irradiation was cut aseptically and then 0.4 g in a sterile ampoule bottle was used as a test sample.

(5)耐光試験後の抗菌性
このようにして得られた試験検体に上記の試験菌液を4mL接種し、35℃で24時間培養した。培養後、滅菌水10mLで洗浄したものを試験液とし、水で希釈し、10倍希釈液を用意した。
(5) Antibacterial activity after light resistance test The test specimen thus obtained was inoculated with 4 mL of the test bacterial solution and cultured at 35 ° C. for 24 hours. After culturing, the sample washed with 10 mL of sterilized water was used as a test solution and diluted with water to prepare a 10-fold diluted solution.

この希釈液をSCDLP(不活化剤含有一般生菌数測定用培地Soybean Casein Digest Agar with Lecithin, Polysobate 80)寒天培地に接種し、35℃で48時間培養した。培養後、形成された集落をカウントし、生菌数(個/mL)を計測し、抗菌性を評価した。これにより、長時間光照射を行なった環境下での本発明例の抗菌作用を確認できる。   This diluted solution was inoculated into SCDLP (Soybean Casein Digest Agar with Lecithin, Polysobate 80), an agar medium containing an inactivation agent, and cultured at 35 ° C. for 48 hours. After culturing, the formed colonies were counted, the number of viable bacteria (cells / mL) was counted, and antibacterial properties were evaluated. Thereby, the antibacterial action of the example of the present invention in an environment where light irradiation is performed for a long time can be confirmed.

比較のため、耐光試験前の銀コバルト錯体含浸基材(コントロール)について上記と同様の実験を行った。これにより、光照射を行なわない通常環境下での本発明例の抗菌作用を確認できる。   For comparison, an experiment similar to the above was performed on a silver-cobalt complex-impregnated base material (control) before the light resistance test. Thereby, the antibacterial action of the example of the present invention under a normal environment where no light irradiation is performed can be confirmed.

(6)耐光試験後の抗カビ性
このようにして得られた試験検体に上記の試験検体に各試験胞子液を4mLずつ接種し、25℃で24時間培養した。培養後、滅菌水10mLで洗浄し、水で希釈して10倍希釈液を得た。
(6) Antifungal property after light resistance test Each of the test specimens thus obtained was inoculated with 4 mL of each test spore solution and cultured at 25 ° C. for 24 hours. After culturing, it was washed with 10 mL of sterilized water and diluted with water to obtain a 10-fold diluted solution.

このようにして得られた希釈液をGPLP(不活化剤含有真菌数測定用培地、Glucose Peptone Broth with Lecithin,Polysorbate 80)寒天培地に接種し、25℃で5日間培養した。培養後、形成された集落をカウントし、胞子数(個/mL)を計測し、耐光試験後の抗カビ性を評価した。これにより、長時間光照射を行なった環境下での本発明例の抗カビ作用を確認できる。   The diluted solution thus obtained was inoculated on GPLP (inactivating agent-containing fungal count measuring medium, Glucose Peptone Broth with Lecithin, Polysorbate 80) agar medium and cultured at 25 ° C. for 5 days. After culturing, the formed colonies were counted, the number of spores (number / mL) was counted, and the antifungal property after the light resistance test was evaluated. Thereby, the antifungal action of the example of the present invention in an environment where light irradiation is performed for a long time can be confirmed.

比較のため、耐光試験前の銀コバルト含浸基材(コントロール)について上記と同様の実験を行った。これにより、光照射を行なわない通常環境下での本発明例の抗カビ作用を確認できる。   For comparison, an experiment similar to the above was performed on a silver cobalt impregnated base material (control) before the light resistance test. Thereby, the anti-fungal action of the example of the present invention in a normal environment where no light irradiation is performed can be confirmed.

これらの結果を表8〜表13(基材への塗布濃度3000ppm)に示す。   These results are shown in Tables 8 to 13 (coating concentration on the base material of 3000 ppm).

はじめに、抗菌性(表8〜11を参照)について考察する。   First, antibacterial properties (see Tables 8 to 11) will be considered.

まず、各表の「耐光試験前スパンレース不織布」の結果を参照する。初発菌数に比べて48時間後の生菌数が減少した場合、本発明例の銀コバルト錯体は、光照射を行なわない通常環境下で抗菌作用を有しているといえる。表8〜11を参照すると、いずれの菌についても、初発菌数に比べて48時間後の生菌数は減少し、本発明例が広範囲の抗菌作用を有することが確認された。特に、黄色ブドウ球菌(表8)および枯草菌(表11)に対しては、48時間後の生菌数が10個/mL未満となり、極めて強い抗菌作用が確認された。   First, the results of “spun lace nonwoven fabric before light resistance test” in each table are referred to. When the number of viable bacteria after 48 hours is reduced compared to the initial number of bacteria, it can be said that the silver-cobalt complex of the example of the present invention has an antibacterial action under a normal environment where no light irradiation is performed. Referring to Tables 8 to 11, the number of viable bacteria after 48 hours was reduced for all the bacteria compared to the initial number of bacteria, and it was confirmed that the examples of the present invention have a wide range of antibacterial effects. In particular, for Staphylococcus aureus (Table 8) and Bacillus subtilis (Table 11), the viable count after 48 hours was less than 10 cells / mL, and an extremely strong antibacterial action was confirmed.

次いで、各表の「耐光試験後スパンレース不織布」の結果を参照する。初発菌数に比べて48時間後の生菌数が減少した場合、本発明例の銀コバルト錯体は、長時間光照射を行なった環境下(直射日光下で約1年間照射に相当する環境下)で抗菌作用を有しているといえる。表8〜11を参照すると、いずれの菌についても、初発菌数に比べて48時間後の生菌数は減少し、本発明例が、耐光試験後も広範囲の抗菌作用を持続していることが確認された。特に、黄色ブドウ球菌(表8)および枯草菌(表11)に対しては、48時間後の生菌数が10〜10個/mLオーダーまで減少し、極めて強い抗菌作用が確認された。 Next, the results of “Spunlaced nonwoven fabric after light resistance test” in each table are referred to. When the number of viable bacteria after 48 hours is reduced compared with the initial number of bacteria, the silver-cobalt complex of the present invention example is subjected to light irradiation for a long time (in an environment corresponding to irradiation for about one year under direct sunlight). It can be said that it has an antibacterial action. Referring to Tables 8 to 11, the number of viable bacteria after 48 hours decreased for all the bacteria compared to the initial number of bacteria, and the present invention example maintained a wide range of antibacterial effects even after the light resistance test. Was confirmed. In particular, for Staphylococcus aureus (Table 8) and Bacillus subtilis (Table 11), the number of viable bacteria after 48 hours was reduced to 10 3 to 10 2 cells / mL order very strong antibacterial effect was confirmed .

次に、抗カビ性(表12、13を参照)について考察する。本実施例の抗カビ試験は、使用したカビの胞子が胞子→菌糸→胞子と順次増殖していく胞子数(各表では「生菌数」と記載)を測定するものであり、慣用のJIS Z2911に記載のカビ抵抗性試験(カビの胞子から菌糸の発育だけを評価する定性試験)に比べ、抗カビ性を定量的に評価する試験である。この抗カビ試験によれば、初発菌数(初発胞子数)に比べて5日後の生菌数が有意に超えていなければ、「抗カビ性あり」と評価できる。   Next, antifungal properties (see Tables 12 and 13) will be considered. The anti-fungal test of this example is to measure the number of spores (the number of viable cells described in each table) in which the mold spores used grow in the order of spores → mycelium → spores. This is a test for quantitatively evaluating the antifungal property as compared with the fungus resistance test described in Z2911 (a qualitative test for evaluating only the growth of mycelia from mold spores). According to this anti-fungal test, if the number of viable bacteria after 5 days is not significantly greater than the initial bacterial count (the number of initial spores), it can be evaluated as “anti-fungal”.

まず、各表の「耐光試験前スパンレース不織布」の結果を参照する。クロカビに対しては、表12に示すように、初発菌数に比べて5日後の生菌数が有意に減少しており、優れた抗カビ作用が確認された。また、ススカビに対しては、表13に示すように、クロカビよりも効果が若干劣るものの、5日後の生菌数の有意な増加は認められず、抗カビ作用が確認された。   First, the results of “spun lace nonwoven fabric before light resistance test” in each table are referred to. For black mold, as shown in Table 12, the number of viable bacteria after 5 days was significantly reduced compared with the number of the first bacteria, and an excellent antifungal action was confirmed. In addition, as shown in Table 13, the effect on fungi was slightly inferior to that of black mold, but a significant increase in the number of viable bacteria after 5 days was not recognized, and an antifungal action was confirmed.

次いで、各表の「耐光試験後スパンレース不織布」の結果を参照する。上記と同様の傾向は、長時間光照射を行なった環境下でも見られた。詳細には、クロカビに対しては、表12に示すように、初発菌数に比べて5日後の生菌数が有意に減少しており、耐光試験後も優れた抗カビ作用が確認された。また、ススカビに対しては、表13に示すように5日後の生菌数の有意な増加は認められず、耐光試験後も抗カビ作用が確認された。   Next, the results of “Spunlaced nonwoven fabric after light resistance test” in each table are referred to. The same tendency as described above was observed even in an environment where light irradiation was performed for a long time. Specifically, for black mold, as shown in Table 12, the number of viable bacteria after 5 days was significantly reduced compared to the number of initial bacteria, and an excellent antifungal action was confirmed even after the light resistance test. . In addition, as shown in Table 13, no significant increase in the number of viable bacteria was observed after 5 days, and antifungal activity was confirmed even after the light resistance test.

上記の実験結果より、本発明の銀コバルト錯体は、良好な抗菌・抗かび作用を有しており、上記作用は、耐光試験後も充分に維持されていることが確認された。   From the above experimental results, it was confirmed that the silver-cobalt complex of the present invention has a good antibacterial and antifungal action, and the above action is sufficiently maintained even after the light resistance test.

Claims (3)

下式(1)で表されるCo−Ag−Coの三核錯体を含有することを特徴とする抗菌性および抗カビ性の両方に優れた抗菌・抗カビ剤。

式中、
nは1〜3の整数であり、
1〜R12は同一または異なって、Hまたは炭素数が1〜6のアルキル基であり、
Nに結合するR1〜R3のいずれかの基、R4〜R6のいずれかの基、R7〜R9
いずれかの基、R10〜R12のいずれかの基は、他のいずれかの基と架橋結合を有
していても良く、
13は、Hまたは炭素数が1〜6のアルキル基である。
An antibacterial and antifungal agent excellent in both antibacterial and antifungal properties, comprising a Co-Ag-Co trinuclear complex represented by the following formula (1).

Where
n is an integer of 1 to 3,
R 1 to R 12 are the same or different and are H or an alkyl group having 1 to 6 carbon atoms;
Any group of R 1 to R 3 bonded to N, any group of R 4 to R 6 , any group of R 7 to R 9 , and any group of R 10 to R 12 It may have a crosslink with any group of
R 13 is H or an alkyl group having 1 to 6 carbon atoms.
下式(2)、下式(3)、および下式(4)で表されるCo−Ag−Coの三核錯体の少なくとも一種を含有する請求項1に記載の抗菌・抗カビ剤。



式中、nおよびR13は前と同じ意味である。
The antibacterial / antifungal agent according to claim 1, comprising at least one of Co-Ag-Co trinuclear complexes represented by the following formula (2), the following formula (3), and the following formula (4).



In the formula, n and R 13 have the same meaning as before.
光および無機塩に対する耐久性に優れたものである請求項1または2に記載の抗菌・抗カビ剤。The antibacterial and antifungal agent according to claim 1 or 2, which has excellent durability against light and inorganic salts.
JP2009075819A 2008-03-26 2009-03-26 Antibacterial and antifungal agents Expired - Fee Related JP5522428B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009075819A JP5522428B2 (en) 2008-03-26 2009-03-26 Antibacterial and antifungal agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008082005 2008-03-26
JP2008082005 2008-03-26
JP2009075819A JP5522428B2 (en) 2008-03-26 2009-03-26 Antibacterial and antifungal agents

Publications (2)

Publication Number Publication Date
JP2009256346A JP2009256346A (en) 2009-11-05
JP5522428B2 true JP5522428B2 (en) 2014-06-18

Family

ID=41384237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009075819A Expired - Fee Related JP5522428B2 (en) 2008-03-26 2009-03-26 Antibacterial and antifungal agents

Country Status (1)

Country Link
JP (1) JP5522428B2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3162871B2 (en) * 1993-04-26 2001-05-08 明治乳業株式会社 Antibacterial antifungal antiviral agent
KR100411178B1 (en) * 2000-10-09 2003-12-18 한국화학연구원 Novel antibacterial agents, and antibacterial and deordorizing solution comprising them

Also Published As

Publication number Publication date
JP2009256346A (en) 2009-11-05

Similar Documents

Publication Publication Date Title
Rowan et al. ‘Silver bullets’ in antimicrobial chemotherapy: Synthesis, characterisation and biological screening of some new Ag (I)-containing imidazole complexes
Olar et al. N, N-dimethylbiguanide complexes displaying low cytotoxicity as potential large spectrum antimicrobial agents
Chrysouli et al. Ciprofloxacin conjugated to diphenyltin (IV): a novel formulation with enhanced antimicrobial activity
Mirjalili et al. Antibacterial properties of nano silver finish cellulose fabric
McGinley et al. Imidazole Schiff base ligands: Synthesis, coordination complexes and biological activities
Emen et al. Synthesis, Characterization and Antimicrobial Activities of Some Metal Complexes with N-(2-Chloro-benzoyl) thiourea Ligands: The Crystal Structure of fac-[CoL~ 3] and cis-[PdL~ 2]
Gölcü Transition metal complexes of propranolol dithiocarbamate: synthesis, characterization, analytical properties and biological activity
Dias et al. New di‐and triorganotin (IV) carboxylates derived from a Schiff base: synthesis, characterization and in vitro antimicrobial activities
US5468738A (en) Fungicide and its use
Chohan Metal-based antibacterial and antifungal sulfonamides: synthesis, characterization, and biological properties
Jiang et al. Synthesis, characterization and antibacterial activity of a biocompatible silver complex based on 2, 2′-bipyridine and 5-sulfoisophthalate
JP5435546B2 (en) Silver cobalt complex and antibacterial / antifungal agent
Yousif et al. Synthesis, structure and antibacterial activity of some triorganotin (IV) complexes with a benzamidoalanine ligand
McCann et al. Silver (I) complexes of 9-anthracenecarboxylic acid and imidazoles: synthesis, structure and antimicrobial activity
Banti et al. Hydrogels containing water soluble conjugates of silver (I) ions with amino acids, metabolites or natural products for non infectious contact lenses
Vijayakumar et al. Chitosan with pendant (E)-5-((4-acetylphenyl) diazenyl)-6-aminouracil groups as synergetic antimicrobial agents
Aljahdali Nickel (II) complexes of novel thiosemicarbazone compounds: Synthesis, characterization, molecular modeling and in vitro antimicrobial activity
Andotra et al. Synthesis, spectroscopic, DFT and in vitro biological studies of vanadium (III) complexes of aryldithiocarbonates
JP5522428B2 (en) Antibacterial and antifungal agents
Patel et al. Synthesis, characterization, and thermal and biocidal aspects of drug-based metal complexes
Tohidian et al. Two new Cu (II) and Zn (II) Schiff base complexes: synthesis, characterization and their biological activity
El-Sayed et al. Synthesis, characterization of Lanthanum mixed ligand complexes based on benzimidazole derivative and the effect of the added ligand on the antimicrobial, and anticancer activities
CN112830940B (en) 2,5-furandicarbaldehyde oxime metal complex, preparation method thereof, and application in antibacterial and mildew-removing disinfectant
JP5435547B2 (en) Silver zinc complex and antibacterial / antifungal agent
Kaygusuz et al. Antimicrobial nano-Ag-TiO2 coating for lining leather

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140207

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140326

R150 Certificate of patent or registration of utility model

Ref document number: 5522428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees